Literature DB >> 2299713

Extracorporeal shock wave lithotripsy monotherapy for staghorn stones with the second generation lithotriptors.

H Vandeursen1, L Baert.   

Abstract

We reviewed 50 patients with staghorn stones to determine whether extracorporeal shock wave lithotripsy monotherapy is a successful alternative to the classical approaches (open operation versus percutaneous lithotripsy alone or with extracorporeal shock wave lithotripsy). Results free of stones at long-term followup (greater than 3 months) were obtained in 28 of 50 patients (56%) and when we included residual fragments with a diameter of less than 4 mm. (9 patients, or 18%) an over-all success rate of 74% (37 patients) was achieved. Of the patients 41 had a Double-J stent to improve fragment evacuation (5 experienced obstructive elimination), while uncomplicated evacuation was noted in the remaining 9 without a stent. No case of septicemia after extracorporeal shock wave lithotripsy was observed but all patients had received strict antimicrobial prophylaxis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2299713     DOI: 10.1016/s0022-5347(17)39925-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

1.  Strategic lithotripsy using the Doli S EMSE 220 F-XP for the management of staghorn renal calculi.

Authors:  Ioannis Heretis; Charalampos Mamoulakis; Vaios Papadimitriou; Frank Sofras
Journal:  Int Urol Nephrol       Date:  2010-06-08       Impact factor: 2.370

Review 2.  ESWL '90--state of the art. Limitations and future trends of shock-wave lithotripsy.

Authors:  J Rassweiler; P Alken
Journal:  Urol Res       Date:  1990

3.  Treatment of ureteral and renal stones by electrohydraulic lithotripsy.

Authors:  H Başar; N Ohta; S Kageyama; K Suzuki; K Kawabe
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

4.  Open stone surgery: is it still a preferable procedure in the management of staghorn calculi?

Authors:  A A Esen; Z Kirkali; C Güler
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.